Product Images Clopidogrel

This appears to be a table showing the hazard ratios for different subgroups based on patient characteristics and on-study medications/interventions in the CURE study. The table includes information on the number of participants in each subgroup, the percentage of patients in each group who received clopidogrel or placebo, and whether clopidogrel or placebo was favored. The hazard ratios for each subgroup are also shown.*

The given text seems to be some data from a COMMIT study, analyzing the effects of adding Clopidogrel to Aspirin on the primary endpoint. The data is presented in the form of tables displaying results for different subgroups based on various factors like gender, heart rate, and fibrinolytic agent given. The table contains columns showing the number of participants, percentage of participants, and odds ratio. The last row provides information about the overall result of the study with a 95% confidence interval.*

The image shows the cumulative event rates of fatal or non-fatal vascular events in the CAPRIE study for the drug clopidogrel over a period of 24 months of follow-up, with a statistical comparison to other treatments.*

This is a figure presenting the effects of co-administered proton pump inhibitors (PPIs) on the exposure to Clopidogrel active metabolite. The data represents the mean and 90% confidence interval of the area under the curve (AUC) for the active metabolite when administered alone or in combination with different PPIs (Dexlansoprazole, Lansoprazole, Pantoprazole, Omeprazole). The x-axis shows the time in hours (0-12) and the y-axis shows the percentage change relative to the administration of Clopidogrel alone.*

The image displays a graph showing the cumulative event rates of cardiovascular death, myocardial infarction, and stroke in the CURE study. The horizontal axis shows the months of follow-up while the vertical axis indicates the percentage of patients experiencing the combined events. The study compared clopidogrel (+aspirin) treatment to a placebo (+aspirin) treatment. Other standard therapies were also used as appropriate. The results showed a significant reduction in the combined events for the clopidogrel (+aspirin) group compared to the placebo (+aspirin) group, with a p-value of 0.00009.*

This is a figure from the COMMIT Study showing the cumulative event rates for the combined endpoint of re-infarction, stroke or death. The study compared a placebo group with a group receiving Clopidogrel. The placebo group had 2310 patients with events (10.1%), while the group receiving Clopidogrel had 2121 patients with events (8.2%). There was a 9% proportional risk reduction, resulting in a 0.006% absolute risk reduction in deaths. The endpoint events occurred within the first 28 days of the study. All patients in the study received aspirin.*